~~<i id='C45922F231'><strike id='C45922F231'><tt id='C45922F231'><pre id='C45922F231'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：entertainment 2025-10-01 00:06:26 - browse：9

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Hospitals need to get ahead of regulations on climate change

entertainment

explore

focus

hotspot

entertainment

leisure time

AlexHogan/STATIntheaftermathofthepolicemurderofGeorgeFloydandsubsequentBlackLivesMatterprotestsacros

WSS

Change Healthcare cyberattack outage could last weeks

House looks to weaken Medicare negotiation

Pfizer highlights cancer drugs it thinks could reignite investor interest

Clinicians often fail to acknowledge the pain caused by long Covid

Should insurance cover cosmetic surgery?

How to address the problem of discarded donor organs

explore

entertainment

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

A Q&A with Aletha Maybank, AMA’s chief health equity officer

United colonoscopy coverage change 'may cost lives,' doctors say

Kenai launches with $82 million for Parkinson’s stem cell therapy

Tori Bowie and the unacceptable rates of Black maternal death

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

In age of alternative facts, a scholarly course on calling out crap

The Bio Revolution is changing business and society

Malaria cases in Florida and Texas: Here’s what you need to know

Achieving telehealth equity for people with hearing loss

explore

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

The Bio Revolution is changing business and society

FDA does about

Some medical students still think black patients feel less pain

Bird flu makes raw milk dangerous to consume, mouse study finds

Protect nursing home residents from future pandemics

focus

hotspot

entertainment

leisure time